Potential treatment alternatives include BRAF/MEK inhibitors, which have been useful in the treatment of various cancers like CDKN2A-negative melanoma, and CDK4/6 inhibitors, which have been approved to treat breast cancer. This evidence concerns the gene CDKN2A and breast cancer.